Generic placeholder image

Current Respiratory Medicine Reviews

Editor-in-Chief

ISSN (Print): 1573-398X
ISSN (Online): 1875-6387

Research Article

The Prognostic Effect of Clinical and Laboratory Findings on in-hospital Mortality in Patients with Confirmed COVID-19 Disease

Author(s): Ali Jangjou, Razieh Sadat Mousavi-Roknabadi*, Hossein Faramarzi, Alireza Neydani, Seyed Rouhollah Hosseini-Marvast and Mostafa Moqadas

Volume 18, Issue 2, 2022

Published on: 02 June, 2022

Page: [134 - 141] Pages: 8

DOI: 10.2174/1573398X18666220413113142

Price: $65

Abstract

Background: COVID-19 is known as a global health issue, which can cause high morbidity and mortality in patients. It is necessary to identify biomarkers, clinical and laboratory findings and effects on patients' mortality.

Objective: This study aimed to evaluate the prognostic effect of clinical and laboratory findings on in-hospital mortality in patients with confirmed COVID-19.

Methods: This retrospective cross-sectional study (February-August 2020) was conducted on adult patients with COVID-19 who were hospitalized in one of the main reference hospitals affiliated with Shiraz University of Medical Sciences, southern Iran. Patients with uncompleted or missed medical files were excluded from the study. Clinical and laboratory findings were extracted from the patients' medical files and then analyzed. The patients were categorized and later compared as survivor and nonsurvivors groups.

Results: 345 patients were enrolled and 205 (59.4%) were male. The mean±SD of age was 53.67±16.97 years, and 32 (9.3%) out of the total did not survive. Hypertension (28.4%) and diabetes (25.5%) were the most prevalent comorbidities. All clinical symptoms were similar in both groups, except fever, which was observed significantly more in nonsurvivors (P=0.027). The duration of hospitalization was 9.20±5.62 (range; 2-42) days, which was higher in nonsurvivors (P<0.001). The results of Multivariate Logistic Regression Model showed that CRP (OR=1.032, P=0.01) and INR (OR=48.88, P=0.049) were the predictor factors for in-hospital mortality in hospitalized patients with confirmed COVID-19.

Conclusion: The current study showed that in-hospital mortality was 9.3%. It was found that CRP and INR were the predictor factors for in-hospital mortality in hospitalized patients with confirmed COVID-19.

Keywords: COVID-19, laboratory diagnosis, prognosis factors, mortality, prognostic, effect, hypertension.

Graphical Abstract
[1]
Ebrahimi V, Sharifi M, Mousavi-Roknabadi RS, et al. Predictive determinants of overall survival among re-infected COVID-19 patients using the elastic-net regularized Cox proportional hazards model: A machine-learning algorithm. BMC Public Health 2022; 22(1): 10.
[http://dx.doi.org/10.1186/s12889-021-12383-3] [PMID: 34986818]
[2]
Sharifi M, Khademian MH, Mousavi-Roknabadi RS, Ebrahimi V, Sadegh R. A new rapid approach for predicting death in coronavirus patients: The development and validation of the COVID-19 risk-score in fars province (CRSF). Iran J Public Health 2022; 51(1): 178-87.
[http://dx.doi.org/10.18502/ijph.v51i1.8310] [PMID: 35223639]
[3]
Sahu KK, Mishra AK, Lal A. COVID-2019: Update on epidemiology, disease spread and management. Monaldi Arch Chest Dis 2020; 90(1): 197-205.
[http://dx.doi.org/10.4081/monaldi.2020.1292] [PMID: 32297723]
[4]
Mousavi-Roknabadi RS, Haddad F, Fazlzadeh A, Kheirabadi D, Dehghan H, Rezaeisadrabadi M. Investigation of plasma exchange and hemoperfusion effects and complications for the treatment of patients with severe COVID-19 (SARS-CoV-2) disease: A systematic scop-ing review. J Med Virol 2021; 93(10): 5742-55.
[http://dx.doi.org/10.1002/jmv.27182] [PMID: 34228355]
[5]
Kheirabadi D, Haddad F, Mousavi-Roknabadi RS, Rezaeisadrabadi M, Dehghan H, Fazlzadeh A. A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID-19 (SARS-CoV-2) pandemic. J Med Virol 2021; 93(5): 2705-21.
[http://dx.doi.org/10.1002/jmv.26811] [PMID: 33463727]
[6]
Ahn D-G, Shin H-J, Kim M-H, et al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). J Microbiol Biotechnol 2020; 30(3): 13-324.
[7]
Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chem Lab Med 2020; 58(7): 1021-8.
[http://dx.doi.org/10.1515/cclm-2020-0369] [PMID: 32286245]
[8]
Tan C, Huang Y, Shi F, et al. C‐reactive protein correlates with computed tomographic findings and predicts severe COVID‐19 early. J Med Virol 2020; 856-62.
[http://dx.doi.org/10.1002/jmv.25871]
[9]
Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID-19. Am J Hematol 2020; 95(7): 834-47.
[http://dx.doi.org/10.1002/ajh.25829] [PMID: 32282949]
[10]
Li H, Xiang X, Ren H, et al. SAA is a biomarker to distinguish the severity and prognosis of Coronavirus Disease 2019 (COVID-19). J Infect 2020; 80: 646-55.
[http://dx.doi.org/10.1016/j.jinf.2020.03.035] [PMID: 32277967]
[11]
Cai Q, Huang D, Yu H, et al. COVID-19: Abnormal liver function tests. J Hepatol 2020; 73(3): 566-74.
[http://dx.doi.org/10.1016/j.jhep.2020.04.006] [PMID: 32298767]
[12]
Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection. Lancet Infect Dis 2020; 20(7): 773.
[http://dx.doi.org/10.1016/S1473-3099(20)30195-X] [PMID: 32171390]
[13]
Meo SA, Al-Khlaiwi T, Usmani AM, Meo AS, Klonoff DC, Hoang TD. Biological and epidemiological trends in the prevalence and mortal-ity due to outbreaks of novel coronavirus COVID-19. J King Saud Univ Sci 2020; 32(4): 2495-9.
[http://dx.doi.org/10.1016/j.jksus.2020.04.004] [PMID: 32292261]
[14]
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020; 395(10223): 507-13.
[http://dx.doi.org/10.1016/S0140-6736(20)30211-7] [PMID: 32007143]
[15]
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospec-tive cohort study. Lancet 2020; 395(10229): 1054-62.
[http://dx.doi.org/10.1016/S0140-6736(20)30566-3] [PMID: 32171076]
[16]
Li J, Huang DQ, Zou B, et al. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol 2021; 93(3): 1449-58.
[17]
Liang Y, Wang M-L, Chien C-S, et al. Highlight of immune pathogenic response and hematopathologic effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 infection. Front Immunol 2020; 11: 1022.
[http://dx.doi.org/10.3389/fimmu.2020.01022] [PMID: 32574260]
[18]
Zheng F, Tang W, Li H, Huang YX, Xie YL, Zhou ZG. Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. Eur Rev Med Pharmacol Sci 2020; 24(6): 3404-10.
[PMID: 32271459]
[19]
Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18(4): 844-7.
[http://dx.doi.org/10.1111/jth.14768] [PMID: 32073213]
[20]
Zou X, Li S, Fang M, et al. Acute physiology and chronic health evaluation ii score as a predictor of hospital mortality in patients of Coronavirus Disease 2019. Crit Care Med 2020; 48(8): e657-65.
[http://dx.doi.org/10.1097/CCM.0000000000004411] [PMID: 32697506]
[21]
Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020; 75(7): 1730-41.
[http://dx.doi.org/10.1111/all.14238] [PMID: 32077115]
[22]
Wei Y, Zeng W, Huang X, et al. Clinical characteristics of 276 hospitalized patients with coronavirus disease 2019 in Zengdu District, Hubei Province: A single-center descriptive study. BMC Infect Dis 2020; 20(1): 549.
[http://dx.doi.org/10.1186/s12879-020-05252-8] [PMID: 32727456]
[23]
Dong X, Cao Y-Y, Lu X-X, et al. Eleven faces of coronavirus disease 2019. Allergy 2020; 75(7): 1699-709.
[http://dx.doi.org/10.1111/all.14289] [PMID: 32196678]
[24]
Cao Y, Liu X, Xiong L, Cai K. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: A systematic review and meta-analysis. J Med Virol 2020; 92(9): 1449-59.
[http://dx.doi.org/10.1002/jmv.25822] [PMID: 32242947]
[25]
Zhang ZL, Hou YL, Li DT, Li FZ. Laboratory findings of COVID-19: A systematic review and meta-analysis. Scand J Clin Lab Invest 2020; 80(6): 441-7.
[http://dx.doi.org/10.1080/00365513.2020.1768587] [PMID: 32449374]
[26]
Wang G, Wu C, Zhang Q, et al. C-reactive protein level may predict the risk of COVID-19 aggravation. Open Forum Infect Dis 2020; 7(5): ofaa153.
[http://dx.doi.org/10.1093/ofid/ofaa153]
[27]
Li X, Wang L, Yan S, et al. Clinical characteristics of 25 death cases with COVID-19: A retrospective review of medical records in a single medical center, Wuhan, China. Int J Infect Dis 2020; 94: 128-32.
[28]
Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus dis-ease 2019 (COVID-19): A meta-analysis. J Med Virol 2020; 92(10): 1733-4.
[http://dx.doi.org/10.1002/jmv.25819] [PMID: 32242950]
[29]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[30]
Qu R, Ling Y, Zhang YH, et al. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. J Med Virol 2020; 92(9): 1533-41.
[http://dx.doi.org/10.1002/jmv.25767] [PMID: 32181903]
[31]
Omrani-Nava V, Maleki I, Ahmadi A, et al. Evaluation of hepatic enzymes changes and association with prognosis in COVID-19 patients. Hepat Mon 2020; 20(4): e103179.
[http://dx.doi.org/10.5812/hepatmon.103179]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy